TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Bolt Biotherapeutics Stock

Bolt Biotherapeutics Stock

boltbio.comHealthcareFounded: 2015Funding to Date: $64.6MM

Bolt Biotherapeutics is a biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.

Learn more about Bolt Biotherapeutics IPO
Register for Details

For more details on financing and valuation for Bolt Biotherapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Bolt Biotherapeutics.

Register Today

Team

Management Team

Chih-Ping Liu Ph.D
Co-Founder & President
Randall Schatzman Ph.D
Chief Executive Officer & Board Member
Edgar Engleman
Co-Founder & Board Member
Grant Yonehiro
Chief Business Officer & Chief Operating Officer

Board Members

Ashish Khanna Ph.D
NFLS - Pivotal
Randall Schatzman Ph.D
Edgar Engleman
Peter Moldt
Richard Miller MD
Ken Harrison
Peter Bisgaard
Mahendra Shah

Other companies like Bolt Biotherapeutics in the Healthcare sector

Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Acelyrin
Sector
Healthcare
Last Round Est. Valuation
$809.52MM
Colossal Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.01B
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Artera
Sector
Healthcare
Last Round Est. Valuation
$396.01MM
Pyxis Oncology
Sector
Healthcare
 
 
Alzheon
Sector
Healthcare
Last Round Est. Valuation
$1.53B
Emulate
Sector
Healthcare
Last Round Est. Valuation
$409.37MM

News

PR Newswire 01/09/2020
Bolt Biotherapeutics Expands Scientific Advisory Board with Appointment of Dr. Priti Hegde
/PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform...
FierceBiotech 11/11/2019
Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors
Bolt Biotherapeutics, founded by Stanford immuno-oncology veteran Edgar Engleman, is developing new class of cancer drugs called immune stimulating antibody conjugates. Backed by fresh data from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator, the company is preparing a phase 1 trial.
Xconomy 02/05/2019
Xconomy: Bolt Bio Bags $54M for Drugs that Turn the Heat Up on “Cold” Tumors
In cancer lingo, “cold” tumors are cancers that the immune system doesn’t recognize or respond to, even when immune-stimulating drugs are given. Bolt

Trending Companies

Frequently Asked Questions